{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:14:04Z","timestamp":1779106444628,"version":"3.51.4"},"reference-count":36,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cardiovasc electrophysiol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Obesity represents a prevalent condition with multiple comorbidities, including atrial fibrillation (AF). Dronedarone, an antiarrhythmic drug (AAD), has demonstrated efficacy in patients with paroxysmal\/persistent AF and cardiovascular (CV) risk factors. We aimed to evaluate the efficacy and safety of dronedarone in patients with AF across body mass index (BMI) categories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p>\n                      A post hoc analysis of data from the randomized, double\u2010blind ATHENA trial (NCT00174785), which compared dronedarone with placebo, was conducted across the following BMI categories: normal\/underweight (\u2009&lt;\u200925\u2009kg\/m\u00b2), overweight (25\u201330\u2009kg\/m\u00b2), and obese (\u2009&gt;\u200930\u2009kg\/m\u00b2). The primary outcome was time to first CV hospitalization or death from any cause. Treatment\u2010emergent adverse events (TEAEs) were also assessed. Of 4628 patients, 25% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091143) had BMI\u2009&lt;\u200925\u2009kg\/m\u00b2, 43% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091996) had BMI 25\u201330\u2009kg\/m\u00b2, and 32% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091489) had BMI\u2009&gt;\u200930\u2009kg\/m\u00b2. Compared with placebo, dronedarone significantly reduced the risk of first CV hospitalization or death across all BMI groups with hazard ratios (HRs) ranging from 0.639 (95% confidence interval [CI] 0.524\u20130.780) to 0.818 (95% CI 0.691\u20130.968); no interaction by BMI was noted (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.142). Risk of first hospitalization due to AF recurrence was lower in all BMI groups with dronedarone. All\u2010cause mortality was significantly reduced in normal\/underweight patients (HR 0.551 [95% CI 0.353\u20130.861]), but not in those who had overweight (HR 0.976 [95% CI 0.655\u20131.453]) or obesity (HR 1.184 [95% CI 0.742\u20131.889])(p for interaction=0.048). Incidences of serious TEAEs showed no apparent association with increasing BMI. TEAEs leading to discontinuation (primarily gastrointestinal) were more frequent with dronedarone.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dronedarone is an effective AAD for patients with AF across a range of BMI categories with a manageable safety profile.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Trial Registration:<\/jats:bold>\n                      NCT00174785\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jce.70322","type":"journal-article","created":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T13:25:22Z","timestamp":1774185922000},"page":"969-979","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Dronedarone in Overweight and Obesity: Post Hoc Analysis of the ATHENA Trial"],"prefix":"10.1111","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1611-4443","authenticated-orcid":false,"given":"Mate","family":"Vamos","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Cardiology Center University of Szeged Szeged Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8810-700X","authenticated-orcid":false,"given":"Anna","family":"Vagvolgyi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Endocrinology and Diabetology Center University of Szeged Szeged Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"McKindley","sequence":"additional","affiliation":[{"name":"Sanofi Morristown New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan H.","family":"Hohnloser","sequence":"additional","affiliation":[{"name":"Department of Cardiology J. W. Goethe University Frankfurt am Main Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,22]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae508"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-017-0353-9"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1379109"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.191707"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2019.4513"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.24336"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae176"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001193"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23309"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1139\/cjpp-2019-0125"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2016.03.014"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0803778"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109867"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800456"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.2007.01016.x"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd10080323"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euad023"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2018.11.001"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2024.03.017"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.26430\/CHUNGARICA.2024.54.2.104"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2015.04.004"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euac225"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jce.15141"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01194-3"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03381.x"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph17060693"},{"key":"e_1_2_14_28_1","unstructured":"Pfizer Inc. Cordarone (Amiodarone Hydrochloride) Prescribing Information. November 2016. Accessed July 4 2016 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/018972s052lbl.pdf."},{"key":"e_1_2_14_29_1","unstructured":"Sanofi\u2010Aventis US LLC. Multaq (Dronedarone) Prescribing Information.2025. Accessed July 14 2025 https:\/\/products.sanofi.us\/multaq\/multaq.pdf."},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euaf076"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198106060-00002"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1832-0"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23768"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.114.002046"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eut293"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvab090"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2487"}],"container-title":["Journal of Cardiovascular Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jce.70322","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jce.70322","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jce.70322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:26:29Z","timestamp":1779103589000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jce.70322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,22]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/jce.70322"],"URL":"https:\/\/doi.org\/10.1111\/jce.70322","archive":["Portico"],"relation":{},"ISSN":["1045-3873","1540-8167"],"issn-type":[{"value":"1045-3873","type":"print"},{"value":"1540-8167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,22]]},"assertion":[{"value":"2025-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}